Product Images Duloxetine Delayed-release

The text represents a graph showing the proportion of patients with relapse based on the treatment with either placebo or Duloxetine delayed-release capsules. The X-axis indicates the time frame from randomization to relapse in days, while the Y-axis shows the proportion of patients in percentage. The graph shows that the proportion of patients who relapsed is comparatively lower in those who took Duloxetine delayed-release capsules than Placebo.*

This appears to be a graph showing the proportion of patients experiencing relapse over time. The x-axis represents time in days, and the y-axis shows the proportion of patients with relapse. The graph compares a treatment (likely Duloxetine delayed-release capsules) with a placebo. However, without more context or information, it is difficult to draw further conclusions or provide more detail.*

Not available. The text seems to be a mix of random characters and numbers.*

This text shows two sets of data related to medication effects on patients. The first set indicates the percentage of patients who were improved after taking the medication compared to a placebo. The second set shows the percentage improvement in pain from the baseline after treatment. The medication used was DUL 60/120 mg once daily. The data suggests that the medication had a positive effect on patients, but additional information is needed to determine the significance of these results.*

This appears to be a graph depicting the percentage of patients who improved while taking placebo and DUL (assumed to be a medication). The x-axis shows a range of numbers from 50 to 290, which may represent different time points or levels of pain improvement. The y-axis shows the percentage of patients improved, with the scale ranging from 0 to 100. The graph includes two lines, one for placebo and one for DUL 60 mg once daily. The graph also includes a note about BOCF (baseline observation carried forward), which may be a statistical analysis method. A more detailed explanation or context is not available.*

This is a graph showing the percentage of patients who improved after taking placebo or DUL60/120 mg once daily for pain management. The x-axis shows the percentage of improvement, ranging from 0 to 80 percent. The y-axis indicates the treatment group, where the top group represents the DUL60/120 mg group, and the bottom group represents the placebo group. However, this information is insufficient to know the full context of the study or its purpose.*

This is a package label of a drug named Cymbalta 20mg Capsule manufactured by Towa Pharmaceutical Europe, S.L. The package contains 30 capsules and is set to expire on a specific month and year. It contains a warning mentioning that the drug may cause drowsiness and instructions on how to store it at room temperature. The code at the bottom may be a product identifier, but its exact purpose is not clear.*